Head of Alliance Management & Post-Merger Integration (Biopharma & Rare Disease)
- Samantha Wein
- Apr 16
- 2 min read
Updated: Apr 24
Executive Summary: We are currently representing an elite Biopharma Executive with a PhD from Harvard University and a proven track record of managing multi-billion dollar partnering portfolios. This leader specializes in Alliance Management, Business Development Operations, and Post-Merger Integration (PMI) for publicly traded life science organizations. They have successfully overseen the integration of assets following some of the industry’s largest recent M&A transactions.
Core Competencies & Key Performance Indicators (KPIs):
Strategic Alliance Leadership: Led the integration and management of a $6B partnering portfolio spanning discovery, clinical-stage, and commercial assets.
M&A Expertise: Directed integration teams for landmark acquisitions, including a $39B global merger, ensuring disruption-free transitions across hundreds of functional roles.
Operational Excellence: Built Alliance Management (AM) functions from the ground up for NASDAQ-listed neuro and rare disease companies.
Revenue & Value Growth: Negotiated 100+ licenses and 16+ research collaborations, driving 100% annualized growth in collaboration income over a five-year period.
Global Compliance: Certified Strategic Alliance Professional (CSAP) and ISO 44001 trained, with deep expertise in Joint Steering Committees (JSC) and Joint Venture governance.
Recent Career Highlights:
Senior Director, Alliance Management (Top-Tier Rare Disease Biotech): Established the AM function for a commercial-stage company, managing 18 programs across diverse modalities (Small Molecule, AI-enabled Discovery, etc.).
Head of Alliance & Integration (Global Pharma): Led a team of direct reports within the Business Development & Strategy unit; managed a portfolio of 80+ active parent agreements and launched 8 new alliances valued at $3.5B+.
Strategic Growth Specialist: Spearheaded pre-deal diligence for 8 alliances and 4 acquisitions worth a combined $8B in deal value.
Why This Candidate?
This executive is a rare "bridge" between high-level corporate development and granular operational execution. Whether you are looking to scale your Business Development department, stabilize a Post-Merger Integration, or maximize the value of your Out-Licensing portfolio, this candidate brings Ivy League credentials and "Big Pharma" experience to your leadership team.
Interested in this candidate? To request a resume or schedule an interview, please book a consultation with our team or contact us directly using the links below.
Comments